HEPSERA: 55 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
55
Total FAERS Reports
2 (3.6%)
Deaths Reported
23
Hospitalizations
55
As Primary/Secondary Suspect
5
Disabilities
First Report: 200505 · Latest Report: 201404
What Are the Most Common HEPSERA Side Effects?
#1 Most Reported
Osteomalacia
15 reports (27.3%)
#2 Most Reported
Hypophosphataemia
14 reports (25.5%)
#3 Most Reported
Fanconi syndrome acquired
11 reports (20.0%)
All HEPSERA Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Osteomalacia | 15 | 27.3% | 1 | 10 |
| Hypophosphataemia | 14 | 25.5% | 1 | 8 |
| Fanconi syndrome acquired | 11 | 20.0% | 1 | 4 |
| Drug resistance | 10 | 18.2% | 1 | 2 |
| Hepatitis b dna increased | 10 | 18.2% | 0 | 1 |
| Arthralgia | 9 | 16.4% | 1 | 5 |
| Blood phosphorus decreased | 9 | 16.4% | 0 | 4 |
| Back pain | 8 | 14.6% | 0 | 5 |
| Drug ineffective | 8 | 14.6% | 0 | 0 |
| Bone pain | 7 | 12.7% | 0 | 4 |
| Renal impairment | 7 | 12.7% | 0 | 2 |
| Pain | 6 | 10.9% | 0 | 4 |
| Pain in extremity | 6 | 10.9% | 0 | 2 |
| Condition aggravated | 5 | 9.1% | 0 | 3 |
| Muscular weakness | 5 | 9.1% | 0 | 4 |
| Nephrolithiasis | 5 | 9.1% | 0 | 1 |
| Osteoporosis | 5 | 9.1% | 0 | 4 |
| Proteinuria | 5 | 9.1% | 0 | 0 |
| Renal tubular disorder | 5 | 9.1% | 0 | 2 |
Who Reports HEPSERA Side Effects? Age & Gender Data
Average age: 49.9 years. Most reports from: CN. View detailed demographics →
Is HEPSERA Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2005 | 1 | 0 | 0 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 0 | 0 |
| 2010 | 2 | 0 | 2 |
| 2011 | 4 | 1 | 1 |
| 2012 | 6 | 0 | 3 |
| 2013 | 17 | 0 | 9 |
| 2014 | 3 | 0 | 0 |
What Is HEPSERA Used For?
| Indication | Reports |
|---|---|
| Hepatitis b | 26 |
| Chronic hepatitis b | 19 |
Official FDA Label for HEPSERA
Official prescribing information from the FDA-approved drug label.